UCB, a global biopharmaceutical company, received U.S. FDA approval for RYSTIGGO (rozanolixizumab-noli), for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. RYSTIGGO injection for subcutaneous infusion is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRN), resulting in the reduction of circulating IgG. It is the only FDA-approved t...